日本化学療法学会雑誌第51巻第4号

Similar documents
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1

CHEMOTHERAPY

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis



日本化学療法学会雑誌第64巻第4号


03-b-„FŒ{›xŒ¾-4.02

02-(a)-Łi’ì™·Łv-4.11

Table 1. Antimicrobial drugs using for MIC

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile


日本化学療法学会雑誌第53巻第S-3号


日本化学療法学会雑誌第61巻第6号

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.

Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA

Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT

DIC vegetation 1 nonbacterial thrombogenic e


epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

VOL. 43 NO. 4

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia


Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 Feb CLSI M100-S17benzylpenicillin PCG MIC 0.05 g/ml S. pneumoniae penicillin-susceptible S. pneumon

PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin


CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc


Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone





CHEMOTHERAPY JUNE 1986





THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

CHEMO THE RAPY OCT. 1994

R06_01


180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab

49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e

2.7 臨床概要


Fig. 1 Chemical structure of DL-8280

日本化学療法学会雑誌第53巻第S-1号

1BD BBLCRYSTAL RGP Aerococcus viridans Arcanobacterium pyogenes Bacillus cereus Bacillus licheniformis Bacillus megaterium Bacillus pumilus Bacillus s

Fig.1 Chemical structure of BAY o 9867

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

1272 CHEMOTHERAPY MAR. 1975


N-03.indd


CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

日本化学療法学会雑誌第50巻第6号

Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin

日本化学療法学会雑誌第58巻第4号

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 79)

untitled


988 CHEMOTHERAPY NOV. 1971

Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Assoc


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz

CHEMOTHERAPY


untitled


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz



01-a-‹ä‘㑼‰v-4.03


VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT



Transcription:

000 000 0 000 0 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae penicillinpc intermediate S. pneumoniaepisppc resistant S. pneumoniaeprsp.0. PRSP cefpiromecarbapenemscbps teicoplaninteic QPRDPR 0. ml Enterococcus faecalis Enterococcus faecium TEIC linezolid MIC0. ml MRSAMRSE MIC Enterococcus casseriflavus Enterococcus gallinarum TEIC MRSEStaphylococcus haemolyticus CBPs Bacteroides fragilisprevotella spp CBPs Key words: vancomycin 000 MIC I PCs: benzylpenicillinpcg cefpirome cefoselis cefoperazonecpz cefmetazolecmz latamoxeflmoxflomoxef FMOXcefaclor cefdinir cefpodoxime cefteram cefditorenceftibutencetb cefcapenes 00 CBPs: imipenem U.S.Pharmacopeiameropenem panipenem doripenem No.S : faropenem ampicillinamoxicillinampc FRPMAGs: CEPs: cefazolin tobramycintob arbekacinabk cefotiamu. S. Pharmacopeia NQs: ofloxacin ceftriaxone ceftazidimeu. S. Pharmacopeiacefozopran ciprofloxacinu. S. PharmacopeialevofloxacinORTHO McNEIL

tosufloxacintflx MLs: erythromycin clarithromycinu. S. PharmacopeiarokitamycinRKM azithromycinu. S. Pharmacopeia GPTs: vancomycin teicoplaninteic : sulbactamsbtu. S. Pharmacopeia minocyclineminolinezolidlzd quinupristindalfopristinqprdpr fosfomycinfom sulfamethoxazol trimethoprimst LZDQPRDPR 000 00 0 MANUALOFCLINICAL MICROBIOLOGYSEVENTH EDITION MIC 0 MIC MIC Staphylococcus aureus ATCC Escherichia coli ATCC Enterococcus faecalis ATCC Streptococcus pneumoniae ATCC Bacteroides fragilis ATCC Bacteroides thetaiotaomicron ATCC Mueller Hinton medium MHMDifcoS. pneumoniae MHM yeast extract 0. streptococci MHM MIC Wilkins Chalgren AgarWCADifco MIC II MIC Tables MIC Tables Staphylococcus S. aureus S. aureus MPIPC MIC. mlmethicillin susceptible S. aureus MSSA.MIC. ml methicillin resistant S. aureusmrsa.mssa MRSA Tables MSSA CEPs MIC0. ml MLs MIC0 00 ml MRSA ABKQPRDPR TEIC ST MIC0. ml LZD MIC0 MIC0. ml MIC0 ml S. aureus ABKQPRDPRTEIC ST. ml LZD MIC. ml. S. epidermidis S. epidermidis MPIPC MIC 0.0 ml methicillin susceptible S. epidermidismsse.0mic 0. ml methicillin resistant S. epidermidismr- SE0.0MSSE MRSE 0 Tables lactam MSSE MIC0. ml MRSE MIC0. ml MRSE QPRDPRABK MINO LZD MIC0. ml TEIC MIC. ml. QPRDPRABK LZD. ml QPR DPR 0. ml S. haemolyticus S. haemolyticus Table

000 Table Susceptibility distribution of clinical isolates of MSSA 000 00 00 00 00 00 0 0 00 00 0 0 SBT MPIPC 0 0 0 0 SBTCPZ 0 CMZ FMOX 0 0 S 00 0 0 0 0 0 0 0 0 FRPM 00 00 0 00 00 00 00 00 00 00 00 TOB ABK 00 0 0 TFLX 0 0 0 00 00 RKM 0 00 00 00 MINO 00 0 TEIC LZD 0 QPRDPR 0 0 ST FOM Methicillin susceptible Staphylococcus aureusmpipc MIC: ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

Table Susceptibility distribution of clinical isolates of MRSA 000 00 00 00 00 00 0 0 00 00 0 0 SBT MPIPC 0 00 0 0 00 SBTCPZ 0 0 0 0 0 00 00 00 00 0 0 00 00 00 00 00 0 00 00 CMZ 0 00 FMOX 0 0 00 S 00 00 00 00 00 00 00 0 00 00 00 00 00 00 00 FRPM 0 00 00 0 0 0 TOB ABK 00 00 0 TFLX 0 0 00 00 00 RKM 00 00 00 00 00 00 00 00 MINO TEIC 0 LZD QPRDPR ST FOM 00 00 Methicillin resistant Staphylococcus aureusmpipc MIC: ml MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

000 Table Susceptibility distribution of clinical isolates of MSSE 000 00 00 00 00 00 0 0 00 00 0 0 SBT MPIPC 00 00 00 0 0 00 SBTCPZ 0 0 00 0 0 00 00 0 0 0 CMZ FMOX 0 S 00 0 00 00 00 00 00 0 0 00 FRPM 00 00 0 0 00 00 00 00 00 00 00 00 TOB ABK 0 00 00 TFLX 0 0 0 00 00 RKM 0 0 0 0 00 00 00 MINO 00 TEIC 0 LZD QPRDPR 00 0 ST 00 FOM 0 Methicillin susceptible StaphylococcusepidermidisMPIPC MIC: 00 ml MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

Table Susceptibility distribution of 0 clinical isolates of MRSE 000 00 00 00 0 0 0 0 00 00 0 0 SBT MPIPC 0 0 0 0 00 SBTCPZ 0 0 0 0 0 00 00 00 0 0 CMZ 0 00 FMOX 0 0 0 00 S 00 0 0 00 0 00 00 00 00 00 00 00 FRPM 00 0 0 0 00 0 0 TOB ABK 0 0 0 00 TFLX 0 0 00 RKM 0 0 00 00 00 00 00 00 00 MINO 0 TEIC 0 LZD QPRDPR 00 0 ST 00 FOM 00 00 Methicillin resistant StaphylococcusepidermidisMPIPC MIC: 0 ml MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

000 Table Susceptibility distribution of clinical isolates of Staphylococcus haemolyticus 000 00 00 00 00 00 0 0 00 00 0 0 SBT MPIPC 0 0 0 00 SBTCPZ 0 0 0 00 00 00 00 00 00 00 CMZ 00 FMOX S 00 0 0 00 00 00 00 00 00 00 FRPM 00 00 00 00 0 0 0 TOB ABK 0 0 00 TFLX 0 0 00 0 00 RKM 00 00 00 00 MINO 0 0 TEIC LZD QPRDPR 0 0 0 ST 00 FOM 00 : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

Table Susceptibility distribution of 0 clinical isolates of Staphylococcus saprophyticus 000 00 00 00 00 00 0 0 00 00 0 0 SBT MPIPC 0 0 0 SBTCPZ CMZ FMOX S 00 0 0 FRPM 0 0 0 00 00 00 00 00 00 00 00 TOB ABK 00 00 00 00 TFLX 00 00 RKM 0 0 00 MINO 0 0 TEIC LZD 0 QPRDPR ST FOM 0 : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

000 Table Susceptibility distribution of clinical isolates of Staphylococus lugdunensis MIC ml 000 00 00 00 00 00 0 0 00 00 0 0 SBT MPIPC 00 0 SBTCPZ 0 0 CMZ FMOX 0 S 00 00 0 0 0 FRPM 00 00 00 00 00 00 00 0 00 00 TOB ABK 0 0 00 00 00 00 TFLX 0 0 00 0 00 0 0 00 RKM 0 0 00 00 00 00 MINO 0 00 00 TEIC 0 0 0 LZD 0 QPRDPR 00 00 ST FOM 0 : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

Table Susceptibility distribution of clinical isolates of Staphylococcus warneri MIC ml 000 00 00 00 00 00 0 0 00 00 0 0 SBT MPIPC 0 0 0 0 0 SBTCPZ 0 0 0 0 0 0 CMZ FMOX 0 0 S 00 00 0 0 00 00 0 00 FRPM 0 00 00 0 0 00 00 00 00 00 00 00 00 TOB ABK 00 00 00 TFLX 0 0 0 00 0 00 RKM 0 0 00 00 00 00 MINO 00 00 TEIC 0 0 LZD QPRDPR 0 0 ST FOM 00 SBT: strains : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

000 Table Susceptibility distribution of clinical isolates of Staphylococcus capitis MIC ml 000 00 00 00 00 00 0 0 00 00 0 0 SBT MPIPC 0 00 SBTCPZ 0 0 0 00 00 00 0 00 CMZ 00 FMOX 00 S 00 0 00 0 00 0 0 00 00 00 00 00 00 FRPM 00 00 0 0 TOB ABK 00 00 TFLX 0 0 00 RKM 00 00 00 00 00 00 00 00 MINO 00 TEIC LZD QPRDPR 0 ST FOM 00 00 MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

Table 0 Susceptibility distribution of clinical isolates of miscellaneous coagulase negative staphylococci* MIC ml 000 00 00 00 00 00 0 0 00 00 0 0 SBT MPIPC 0 0 00 00 SBTCPZ 0 0 0 00 0 00 00 00 CMZ 0 FMOX 0 S 00 00 0 0 00 0 00 00 00 0 00 0 FRPM 00 00 00 00 00 00 TOB ABK 00 00 00 TFLX 0 0 00 00 RKM 00 00 00 00 MINO 00 0 TEIC LZD 0 QPRDPR 0 ST FOM 0 00 *S. caprae strains, S. hominis strains, strain each of S. cohnii, S. hyicus, S. schleiferi, and S. simulans : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

000 Table Susceptibility distribution of 0 clinical isolates of Streptococcus pyogenes 000 00 00 00 00 00 0 0 00 00 0 0 AMPC SBT 00 00 00 00 00 00 CPZ 0 0 00 00 00 00 00 00 000 000 00 00 00 00 00 00 000 00 CMZ FMOX 00 0 S 00 0 0 0 00 00 00 000 000 000 00 00 00 00 000 000 000 00 FRPM 00 00 0 0 0 0 000 000 000 000 000 000 000 000 TFLX 0 0 00 00 0 00 00 00 00 00 00 MINO 00 TEIC 0 0 00 0 00 LZD QPRDPR 0 0 ST : ampicillin, AMPC: amoxicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim QPRDPR ABKLZD MIC0. ml. ml TEIC MIC0 ml MIC ml. S. saprophyticus S. saprophyticus 0 Table lactam MIC0. ml lactam RKM MLs MIC. ml

Table Susceptibility distribution of clinical isolates of Streptococcus agalactiae 000 00 00 00 00 00 0 0 00 00 0 0 AMPC SBT 00 00 00 00 00 00 CPZ 0 0 00 0 00 0 00 00 00 00 00 0 00 0 00 00 00 00 CMZ FMOX 0 S 00 0 00 00 00 00 00 00 00 00 00 00 00 00 FRPM 00 00 00 00 00 00 00 00 00 00 TFLX 0 0 0 00 0 0 0 0 00 00 00 00 00 MINO 0 00 TEIC 0 00 0 00 LZD QPRDPR 0 ST : ampicillin, AMPC: amoxicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim S. lugdunensis S. lugdunensis Table lactam MIC0. ml lactam MLsTOB MIC. ml S. warneri S. warneri Table MLs FOM TOB MIC0. ml MIC

000 ml TEIC MIC ml S. capitis S. capitis Table MIC0. ml ABKQPRDPR MINOTEIC LZD. mlst. ml. ml MIC0 Other coagulase negative Staphylococci S. caprae S. hominis S. cohnii S. hyicus S. schleiferi S. simulans Table 0 MINOABKQPRDPR TEIC MIC0. ml lactam MLs FOM S. caprae S. simulans CBPsNQs RKM MLs MIC. ml Streptococcus S. pyogenes S. pyogenes 0 Table CBPs MIC0 0.00 ml AMPC S 00 MIC0 0.0 ml MLsMIC: 0. ml.0minomic:. ml. S. agalactiae S. agalactiae Table MINO MIC0. ml NQsMIC:. ml.mino. S. pneumoniae S. pneumoniae PCG MIC 0.0 ml penicillinpc susceptible S. pneumoniaepssp.mic 0.0 ml 0. ml PC intermediate S. pneumoniaepisp.mic. ml PC resistant S. pneumoniaeprsp 0.PSSPPISP PRSP 0 Tables PSSP lactam MIC0 0. ml CBPs MIC0 0.0 ml CBPs MIC0 PISP 0.0 0.0 mlprsp 0.00. ml lactam MIC0 PSSP PISP PRSP TEICQPRDPR LZD PSSPPISP PRSP MIC0 NQs PSSP PRSP PRSP ml MIC MLs PSSP PSSP PRSP PSSP PISP PRSP MIC0 MIC0 S. mitis groups. sanguis group S. mitis groups. sanguis group Table S. mitis CBPs lactam MLsMINO ST TEICTFLXQPRDPR MIC0 0. ml S. anginosus group S. anginosus group Table lactam 0. ml MIC0 CBPs 0.0 ml MLs Enterococcus E. faecalis E. faecalis Table TEICLZD MIC0..0.. ml MIC0. ml NQs MLs ml MIC 0.. TEIC. ml E. faecium E. faecium Table

Table Susceptibility distribution of clinical isolates of penicillin susceptible Streptococcus pneumoniaepssp 000 00 00 00 00 00 0 0 00 00 0 0 PCG SBT AMPC 00 00 00 00 00 00 00 00 CPZ 0 00 00 00 00 00 00 00 00 00 00 00 0 00 00 CMZ 0 FMOX 00 00 S 00 00 00 00 00 00 00 0 0 00 0 00 FRPM 00 0 0 000 00 000 000 000 00 000 00 TFLX 0 0 00 0 RKM 0 0 0 0 MINO TEIC 0 00 0 00 LZD QPRDPR 0 ST PCG MIC: 00 ml PCG: benzylpenicillin, : ampicillin, SBT: sulbactamampicillin, AMPC: amoxicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim

000 Table Susceptibility distribution of clinical isolates of penicillin intermediate Streptococcus pneumoniaepisp 000 00 00 00 00 00 0 0 00 00 0 0 PCG SBT AMPC 00 0 0 00 CPZ 0 0 0 0 0 CMZ FMOX 0 0 S 00 0 0 0 0 FRPM 00 00 0 00 00 00 00 00 00 00 00 TFLX 0 00 0 RKM 0 00 00 00 MINO TEIC 0 00 0 00 LZD QPRDPR 0 0 ST 0 PCG MIC: 0 ml PCG: benzylpenicillin, : ampicillin, SBT: sulbactamampicillin, AMPC: amoxicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim

Table Susceptibility distribution of clinical isolates of penicillin resistant Streptococcus pneumoniaeprsp 000 00 00 00 00 00 0 0 00 00 0 0 PCG SBT AMPC 0 0 CPZ 0 0 0 CMZ FMOX S 00 0 00 0 0 00 FRPM 0 0 00 0 00 00 00 0 00 0 TFLX 0 0 00 0 RKM 0 0 00 00 00 MINO TEIC 0 0 00 0 00 LZD QPRDPR 0 ST PCG MIC: ml PCG: benzylpenicillin, : ampicillin, SBT: sulbactamampicillin, AMPC: amoxicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim

000 Table Susceptibility distribution of clinical isolates of the Streptococcus mitis groupstreptococcus sanguis group 000 00 00 00 00 00 0 0 00 00 0 0 SBT 00 00 CPZ 0 0 00 00 00 00 0 0 0 CMZ 00 FMOX 0 S 00 0 00 00 00 00 00 00 00 FRPM 00 00 00 00 00 0 TFLX 0 0 00 0 0 00 00 0 MINO 00 TEIC 0 00 00 LZD QPRDPR 0 ST strains S. mitis strains, S. oralis strains, strain each of S. sanguis, S. parasanguis, and S. gordonii : ampicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim TEICLZDQPRDPR MIC0 0.... ml TEIC LZD QPRDPR. ml E. avium E. avium 0 Table 0 ST TEICTFLX MIC0. ml ST TFLX ml

Table Susceptibility distribution of clinical isolates of the Streptococcus anginosus group 000 00 00 00 00 00 0 0 00 00 0 0 SBT 0 00 00 0 0 CPZ 0 0 0 00 0 00 00 0 0 00 00 CMZ FMOX 0 S 00 0 0 0 00 00 00 00 00 00 00 00 FRPM 00 00 0 00 00 00 00 00 00 00 00 TFLX 0 0 00 0 00 00 00 MINO 00 TEIC 00 00 LZD QPRDPR 0 0 ST 00 0 S. anginosus strains, S. constellatus strains, S. intermedius strains : ampicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim MIC TEIC. ml E. raffinosus E. raffinosus Table ST TEIC. ml E. casseriflavus E. gallinarum E. casseriflavus E. gallinarum

000 Table Susceptibility distribution of clinical isolates of Enterococcus faecalis 000 00 00 00 00 00 0 0 00 00 0 0 0 0 0 00 00 00 00 FRPM 0 0 TFLX 0 0 0 0 0 00 00 00 0 00 00 00 00 00 00 TEIC 0 LZD QPRDPR ST MIC ml : ampicillin, : cefozopran, : cefpirome, : cefoselis, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristin dalfopristin, ST: sulfamethoxazole trimethoprim Table Susceptibility distribution of clinical isolates of Enterococcus faecium 000 00 00 00 00 00 0 0 00 00 0 0 00 00 00 00 00 00 00 00 00 00 TFLX 0 0 0 0 0 0 0 00 00 00 TEIC LZD QPRDPR 0 0 ST 0 00 MIC ml : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim

Table 0Susceptibility distribution of 0 clinical isolates of Enterococcus avium 000 00 00 00 00 00 0 0 00 00 0 0 0 00 00 00 00 TFLX 0 TEIC LZD 0 QPRDPR 0 0 ST 0 : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim Table Susceptibility distribution of clinical isolates of Enterococcus raffinosus 000 00 00 00 00 00 0 0 00 00 0 0 0 0 00 00 00 00 00 00 00 00 TFLX 0 0 0 0 TEIC LZD QPRDPR ST 00 0 MIC ml : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim Table E. casseriflavus NQs ST E. gallinarum lactamsnqsst vanc.. ml MIC Peptostreptococcus spp. P. anaerobius 0 P. micros P. magnus P. asaccharolyticus P. hydrogenalis P. vaginalis P. bamesae P. ivorii 0 Table

000 Table Susceptibility distribution of chinical isolates of Enterococcus casseliflavus and Enterococcus gallinarum E. casseliflavus strains 000 00 00 00 00 00 0 0 00 00 0 0 0 TFLX 0 TEIC LZD QPRDPR ST 0 E. gallinarum strains 000 00 00 00 00 00 0 0 00 00 0 0 0 0 0 TFLX 0 TEIC LZD QPRDPR ST 0 00 : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim Peptostreptococcus spp MIC0 0. ml. ml MIC0 CETB CEPs ml MIC CBPs. ml MIC P. anaerobius P. bamesae. ml P. bamesae C. difficile C. difficile Table C. difficile MIC0:. ml PCGMIC0:. ml P. acnes P. acnes Table S 00 MIC0

Table Susceptibility distribution of clinical isolates of Peptostreptococcus spp. 000 00 00 00 00 00 0 0 00 00 0 0 0 0 00 CMZ 00 LMOX FMOX 00 00 CETB S 00 0 00 00 0 00 FRPM 00 0 00 00 00 00 0 *P. anaerobius, 0strains, P. micros strains, strains each of P. magnus, and P. asaccharolyticus, P. hydrogenalis strains, strain each of P. vaginalis, P. bamesae, and P. ivorii : ceftazidime, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, LMOX: latamoxef, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefditoren, CETB: ceftibuten, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : vancomycin Table Susceptibility distribution of clinical isolates of Clostridium difficile 000 00 00 00 00 00 0 0 00 00 0 0 PCG FMOX 0 0 0 PCG: benzylpenicillin, FMOX: flomoxef, : imipenem, : meropenem, : panipenem, : doripenem, : vancomycin 0.0 ml. ml B. fragilis B. fragilis Table FRPM MIC0 0. ml CBPs. ml. ml MIC0 CEPs LMOXFMOX. ml MIC0 Other B. fragilis group B. thetaiotaomicron B. distasonis B. uniformis B. vulgatus Other B. fragilis group Table B. fragilis FRPM MIC0... ml Prevotella spp.

000 Table Susceptibility distribution of clinical isolates of Propionibacterium acnes 000 00 00 00 00 00 0 0 00 00 0 0 0 00 00 FMOX 00 00 CETB S 00 0 00 00 00 00 00 000 00 00 00 00 00 00 :cefotiam, FMOX:flomoxef, :cefaclor, :cefdinir, :cefpodoxime, : cefteram, :cefditoren, CETB:ceftibuten, : cefcapene, :vancomycin Table Susceptibility distribution of clinical isolates of Bacteroides fragilis 000 00 00 00 00 00 0 0 00 00 0 0 SBTCPZ 0 0 0 00 00 00 00 CMZ LMOX FMOX S 00 0 00 00 0 00 00 FRPM 00 0 : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, LMOX: latamoxef, FMOX: flomoxef, : cefdinir, : cefpodoxime, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem P. bivia P. melaninogenica P. intermedia P. oralis P. loesheii P. buccae P. corporis P. oris Table CBPs MIC0 0. ml FMOX MIC0. ml CEPs MIC0 00 ml FMOX 00 ml MIC P. bivia III 000 LZD QPRDPR resistant

Table Susceptibility distribution of clinical isolates of miscellaneous members of the Bacteroides fragilis group* 000 00 00 00 00 00 0 0 00 00 0 0 SBTCPZ 0 00 00 00 00 00 00 00 00 0 CMZ 0 0 LMOX FMOX 00 0 S 00 0 0 00 00 00 0 00 00 00 FRPM 0 *B. thetaiotaomicron strains, B. distasonis strains, B. uniformis strains, B. vulgatus strains : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, LMOX: latamoxef, FMOX: flomoxef, : cefdinir, : cefpodoxime, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem Table Susceptibility distribution of clinical isolates of Prevotella spp 000 00 00 00 00 00 0 0 00 00 0 0 00 00 00 00 FMOX 0 0 0 00 00 0 0 0 0 0 *P. bivia strains, P. melaninogenica strains, P. intermedia strains, strains each of P. oralis, and P. loescheii, straineach of P. buccae, P. corporis, and P. oris : ceftazidime, : cefozopran, : cefpirome, : cefoselis, FMOX: flomoxef, : imipenem, : meropenem, : panipenem, : doripenem EnterococciVRE LZD National Committee for Clinical Laboratory StandardsNC- CLS MIC ml S. aureusmsse E. faecalis E. casseriflavus MIC. ml LZD MRSA Tsiodras VRE Gonzales E. faecalis E. faecium Johnson QPRDPR NS MIC ml E. faecalis E. raffinosus. ml MIC Enterococcus MIC. ml Fluit MRSA MIC ml

000 Sanches MRSA MRSEmethicillin resistant S. haemolyticusmrsh other methicillin resistant coagulase negative StaphylococciMRCNS MRSA TEIC NS TEIC ml ml TEIC. ml MIC MRSE 0 S. haemolyticus S. warneri. ml MIC vanc E. casseriflavus E. gallinarum Sanches Staphylococcus TEIC MRSE.MRSH., Staphylococcus TEIC 00 vana MRSA Morbidity and Mortality Weekly ReportMMWR: 00 MMWR 0: 000 Centers for Disease Control and PreventionCDC S. aureus MRSA.0 0. 0.. 000. 0 000 MRSA. 0. 0... 000 MRSA MRSA ABKQPRDPR ST. ml ABK MIC ml QPRDPR Diekema S. epidermidis MRSE..0 0..000.0 0 MRSE S. epidermidis Coagulase negative staphylococcicns ABKLZDQPRDPR TEIC MRSE S. haemolyticus TEIC S. aureus S. pyogenes lactam S. pyogenes MLs 0. 000 0 Farrell 0 MLs.. S. pneumoniae PISP PRSPPISPPCG MIC 0.00. ml PRSPPCG MIC. ml.0....0...0....0 000..0. PISPPRSP PISPPRSP 000 PISPPRSP PRSP Felmingham Adam Doern Low Perez Trallero 0.........0.... PSSPPISPPRSP Ubukata NS PCG MIC PCG MIC PSSP

PRSP PBP S. pneumoniae PISP+PRSP : 00 :. 0 : 0. :. :. :. :. PSSP 0 0 PRSP CBPsTFLX TEIC 0. ml MIC0 NQs ml MIC Yokota. VRE Karlowsky 0 E. faecalis E. faecium. VRE E. faecalis, E. faecium, E. avium, E. raffinosus, E. casseriflavus, E. gallinarum E. casseriflavus, E. gallinarum E. casseriflavus, E. gallinarum TEICLZD. ml E. faecalis MIC. ml MIC ml NQs MIC: ml Enterococcus NQs Peptostreptococcus spp MIC0 0. ml MIC0. ml MIC. ml P. bamesae C. difficile MIC0. ml Pelaez. B. fragilis MIC0 0.0 ml. ml MIC0. ml. ml B. fragilis CBPs Wexler MIC0 0 Prevotella spp CBPs MIC0 MIC0 B. fragilis MRSA CNS vana VRSA VISA VRE PRSP LZD QPRDPR

000 : Chemotherapy : : Chemotherapy : 0 : Chemotherapy : 0 : Chemotherapy : : Chemotherapy : : : 0000 : : 0 000 Manual of Clinical Microbiology Seventh Edition: American Society for MicrobiologyWashingtonD. C., MIC : MICChemotherapy : 0 MIC : MICChemotherapy : 0 National Committee for Clinical Laboratory StandardsNS: TwelfthInformational Supplement M00 SPerformance Standards for Antimicrobial Susceptibility Testing. WaynePA: NS00 Tsiodras SGold H SSakoulasG et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. LANCET : 0000 Gonzales RSchreckenberger P CGraham M Bet al.: Infections due to vancomycin resistant Enterococcus faecium resistant to linezolid. LANCET : 00 Johnson A PTysall LStockdale M Wet al.: Emerging Linezolid Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Two Austrian Patients in the Same Intensive Care Unit. Eur. J. Clin. Microbiol. Infect. Dis. : 00 Fluit A CWielders C L CVerhoef Jet al.: Epidemiology and Susceptibility of 0 Staphylococcus aureus Isolates from University Hospitals Participating in the European SENTRY Study. J. Clin. Micribiol. : 00 Sanches I SMato RLancastre H Det al.: Patterns of Multidrug Resistance among Methicillin Resistant Hospital Isolates of Coagulase Positive and Coagulase Negative Staphylococci Collected in the International Multicenter Study RESIST in and. Microb. Drug Resist. : 000 : 000 Jpn. J. Antibiotics : 00 Diekema D JPfaller M AJones R Net al.: Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USACanada and Latin America. Int. J. Antimicrob. Agents. : 000 : 000 Jpn. J. Antibiotics : 000 0 Farrell D JMorrissey IBakker Set al.: Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 000 study. J. Antimicrob. Chemother. 0S : 00 : 000 Jpn. J. Antibiotics : 00 : 000 00 cefpodoxime Jpn. J. Antibiotics : 00 Felmingham DReinert R RHirakata Y., et al.: Increasing prevalence of antimicrobial resistance amaong isolates of Streptococcus pneumoniae from the PROTECT surveillance studyand comparative in vitro activity of the ketolidetelithromycin. J. Antimicrob. Chemother. 0S : 00 Adam D: Grobal antibiotic resistance in Streptococcus pneumoniaej. Antimicrob. Chemother. 0:T : 00 Doern G VHeilmann K PHuynh H Ket al.: Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in the United States during 000Including a Comparison of Resistance Rate since. Antimicrob. Agents Chemother. : 00 LowDEAzovedo J DWeiss Ket al.: Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 000. Antimicrob. Agents Chemother. : 000 Perez Trallero EFernandez Mazarrasa CGarcia Rey Cet al.: Antimicrobial Susceptibilities of

Streptococcus pneumoniae and 0 Streptococcus pyogenes Isolates and Their Ecological Relationships: Results of a Year Multicenter Surveillance Study in Spain. Antimicrob. Agents Chemother. : 000 Ubukata KMuraki TIgarashi Aet al.: Identification of Penicillin and other Beta Lactam Resistance in Streptococcus pneumoniae by Polymerase Chain Reaction. J. Infect. Chemother. : 0 Yokota SSato KKuwahara Oet al.: Fluoroquinolone Resistant Streptococcus pneumoniae Strains Occur Frequently in Elderly Patients in Japan. Antimicrob. Agents Chemother. : 00 0 Karlowsky J AKelly L JCritchley I Aet al.: Determining Linezolid s Baseline In Vitro Activity in Canada Using Gram Positive Clinical Isolates Collected prior to Its National Rerease. Antimicrob. Agents Chemother. : 00 : VanAE. faecalis : : VRE linezolid 0: 000 : VRE : 000 Pelaez TAlcala LAlonso Ret al.: Reassessment of Clostridium difficile Susceptibility to Metronidazole and Vancomycin. Antimicrob. Agents Chemother. : 000 Wexler H MMolitoris DSt. John Set al.: InVitro Activities of Faropenem against Strains of Anaerobic Bacteria. Antimicrob. Agents Chemother. : 00 Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial s Antimicrobial activity against gram positive cocci and anaerobic bacteria isolated in 000 Isamu YoshidaYoshiji KimuraIsao Higashiyama Giichi Sugimori and Yoshinori Yamano Discovery Research LaboratoriesShionogi & Co., Ltd., Futaba cho ToyonakaOsaka 0Japan The activity of various antibacterial s against clinical isolates of strains of gram positive cocci0 speciesand strains of anaerobic bacteria specieswas assessed by determining their agar dilution MICs. The strains testedwere clinical isolates obtained in 000 at facilities in Japan. Methicillin resistant strains accounted for. of the Staphylococcus aureus and for.0 of the Staphylococcus epidermidisarbekacinabkquinupristindalfopristinqprdprand vancomycin had high antibacterial activity against methicillin resistant S. aureusmrsaand methicillin resistant S. epidermidismrsewith MIC0 values. ml. PenicillinPC intermediate strains and PC resistant strains accounted for. and 0.respectivelyof the Streptococcus pneumoniae CefpiromecarbapenemsCBPsteicoplaninTEICand QPRDPR displayed high antibacterial activity against PRSPinhibiting the growth of all strains at 0. ml. TEICand linezolid were effective against Enterococcus faecalis and Enterococcus faecium with MIC0 values. ml. No resistant strains were found among the gram positive coccus isolates testedincluding MRSA MRSEand Enterococcus speciesexcept Enterococcus casseriflavus and Enterococcus gallinarumhowever TEIC resistant strains were detected in some speciessuch as MRSE and Staphylococcus haemolyticus Among the anaerobescbps displayed potent antibacterial activity against all anaerobic bacteriahowever thedecrease in susceptibility of Bacteroides fragilis and Prevotella spp. to CBPs should be noted.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック